Synthesis and SAR of 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates

https://doi.org/10.1016/j.bmcl.2012.09.014Get rights and content

Abstract

Prostate specific membrane antigen (PSMA) is recognized as an attractive molecular target for the development of radiopharmaceuticals to image and potentially treat metastatic prostate cancer. A series of novel 99mTc/Re-tricarbonyl radiolabeled PSMA inhibitors were therefore synthesized by the attachment of glutamate-urea-lysine (Glu-urea-Lys) and glutamate-urea-glutamate (Glu-urea-Glu) pharmacophore to single amino acid chelate (SAAC) where the SAAC ligand was either bis(pyridin-2-ylmethyl)amino (DPA), bis((1-methyl-1H-imidazol-2-yl)methyl)amino (NMI), bis((1-(carboxymethyl)-1H-imidazol-2-yl)methyl)amino (CIM) or bis((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)amino (TIM). The in vitro binding affinity of the rhenium complexes was evaluated using PSMA-expressing human prostate cancer LNCaP cells. IC50 values ranged from 3.8 ± 2 to >2000 nM. A linker between the SAAC chelate and pharmacophore was required for high affinity binding. However, extending the length of the linker did not substantially improve binding. PSMA binding was also influenced by the nature of the SAAC chelate. One of the most potent compounds, 23b (IC50 = 4.8 ± 2.7 nM), was radiolabeled with technetium tricarbonyl ({99mTc(CO)3}+) to afford the {99mTc(CO)3}+ complex in excellent yield and high purity. This effort has led to the identification of a diverse series of promising high affinity {99mTc(CO)3}+ radiolabeled PSMA inhibitors.

Section snippets

Acknowledgments

We thank Mr. Jeffrey Muddiman for running high resolution mass spectra.

References and notes (31)

  • R. Alberto et al.

    Coord. Chem. Rev.

    (1999)
  • American Cancer Society, Cancer facts & Figures,...
  • E.D. Cook et al.

    Curr. Oncol. Rep.

    (2011)
  • M. Salagierski et al.

    Cancers

    (2010)
  • M. Agostino et al.

    Curr. Opin. Urol.

    (2011)
  • R.G. Lapidus et al.

    Prostate

    (2000)
  • H. Liu et al.

    Cancer Res.

    (1997)
  • D.B. Sodee et al.

    Prostate

    (1998)
  • L.E. Ponsky et al.

    Prostate Cancer P. D.

    (2002)
  • P.M. Smith-Jones et al.

    J. Nucl. Med.

    (2003)
  • S.R. Banerjee et al.

    J. Med. Chem.

    (2010)
  • Y. Chen et al.

    J. Med. Chem.

    (2008)
  • B. Scher et al.

    Eur. J. Nucl. Med. Mol. Imaging

    (2007)
  • L. Rinnab et al.

    BJU Int.

    (2007)
  • S.N. Reske et al.

    J. Nucl. Med.

    (2006)
  • Cited by (76)

    • The Role of Theranostics in Prostate Cancer

      2021, Seminars in Radiation Oncology
    View all citing articles on Scopus
    View full text